

Farbod Darvishian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7125182/publications.pdf>

Version: 2024-02-01

69
papers

1,861
citations

394421

19
h-index

265206

42
g-index

70
all docs

70
docs citations

70
times ranked

3911
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2733-2743.e9.	0.7	7
2	The histone demethylase PHF8 regulates TGF β 2 signaling and promotes melanoma metastasis. <i>Science Advances</i> , 2022, 8, eabi7127.	10.3	17
3	Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. <i>Modern Pathology</i> , 2022, 35, 1370-1382.	5.5	5
4	Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion. <i>Human Pathology</i> , 2021, 111, 67-74.	2.0	7
5	Breast Cancer Risk Factors and Circulating Anti-M β 4llergic Hormone Concentration in Healthy Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4542-e4553.	3.6	2
6	Genetic profile of primary mucinous cystadenocarcinoma of the breast—A case report. <i>Breast Journal</i> , 2021, 27, 731-734.	1.0	7
7	Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma. <i>Modern Pathology</i> , 2021, 34, 562-571.	5.5	13
8	Functional analysis of RPS27 mutations and expression in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 466-479.	3.3	14
9	Pathologic Evaluation of Breast Tissue From Transmasculine Individuals Undergoing Gender-Affirming Chest Masculinization. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 888-893.	2.5	22
10	Oxidative Phosphorylation Promotes Primary Melanoma Invasion. <i>American Journal of Pathology</i> , 2020, 190, 1108-1117.	3.8	20
11	TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1609-1618.e7.	0.7	14
12	Using digital-image analysis of tumor-infiltrating lymphocytes to predict survival outcomes in primary melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10066-10066.	1.6	1
13	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 180-188.	6.3	74
14	Revisiting multifocal breast cancer: a clonality study of ductal carcinoma using whole exome sequencing. <i>Human Pathology</i> , 2019, 94, 71-77.	2.0	0
15	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. <i>Scientific Reports</i> , 2019, 9, 8572.	3.3	36
16	Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model. <i>Breast Cancer Research</i> , 2019, 21, 42.	5.0	30
17	The Relationship of Breast Density and Positive Lumpectomy Margins. <i>Annals of Surgical Oncology</i> , 2019, 26, 1729-1736.	1.5	8
18	Localized amyloidosis: A diagnostic pitfall in breast pathology. <i>Pathology Research and Practice</i> , 2019, 215, 152699.	2.3	8

#	ARTICLE	IF	CITATIONS
19	Microglandular adenosis is an advanced precursor breast lesion with evidence of molecular progression to matrix-producing metaplastic carcinoma. <i>Human Pathology</i> , 2019, 85, 65-71.	2.0	12
20	Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 430-438.	0.7	22
21	Benign Fibromyxoid Lesion of the Breast: A Distinct Entity From Benign Spindle Cell Tumors of the Mammary Stroma?. <i>International Journal of Surgical Pathology</i> , 2018, 26, 488-493.	0.8	5
22	Missing targets after nipple-sparing mastectomy: A multi-disciplinary approach to avoid an undesirable outcome. <i>Breast Journal</i> , 2018, 24, 678-679.	1.0	3
23	Association between Ki67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging. <i>Journal of Surgical Oncology</i> , 2018, 118, 150-156.	1.7	7
24	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	7.0	253
25	Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21585-e21585.	1.6	2
26	MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 328-338.	3.3	34
27	A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. <i>Cancer Cell</i> , 2017, 31, 804-819.e7.	16.8	233
28	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. <i>Molecular Cell</i> , 2017, 68, 731-744.e9.	9.7	90
29	Multifocal Invasive Ductal Cancer: Distinguishing Independent Tumor Foci From Multiple Satellites. <i>International Journal of Surgical Pathology</i> , 2017, 25, 298-303.	0.8	6
30	Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12541-e12541.	1.6	0
31	Targeting EZH2 in acral lentiginous melanoma (ALM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9534-9534.	1.6	1
32	Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. <i>Journal of Translational Medicine</i> , 2016, 14, 299.	4.4	26
33	BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. <i>Cancer Medicine</i> , 2016, 5, 1183-1193.	2.8	41
34	Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. <i>Human Pathology</i> , 2016, 57, 116-125.	2.0	71
35	Metastatic melanoma outcomes in the era of commercially available targeted therapy and immunotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21017-e21017.	1.6	0
36	Prognostic value of mitoses in thick primary melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21046-e21046.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Impact of aging on immune response and survival in melanoma.. Journal of Clinical Oncology, 2016, 34, e21079-e21079.	1.6	0
38	The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival.. Journal of Clinical Oncology, 2016, 34, 9550-9550.	1.6	0
39	A threshold of clinically significant reduced PTEN expression in melanoma.. Journal of Clinical Oncology, 2016, 34, e21063-e21063.	1.6	0
40	Analysis of TERT promoter mutations, polymorphisms, clinicopathologic features and recurrence-free survival in primary melanoma.. Journal of Clinical Oncology, 2016, 34, e21065-e21065.	1.6	0
41	Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer, 2015, 15, 926.	2.6	2
42	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	47
43	Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. Cancer Immunology Research, 2015, 3, 278-287.	3.4	81
44	FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nature Cell Biology, 2015, 17, 322-332.	10.3	134
45	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clinical Cancer Research, 2015, 21, 4903-4912.	7.0	73
46	A Note of Caution. International Journal of Surgical Pathology, 2015, 23, 549-552.	0.8	2
47	Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.. Journal of Clinical Oncology, 2015, 33, e20057-e20057.	1.6	1
48	Angiosarcoma of the Breast Masquerading as Hemangioma: Exploring Clinical and Pathological Diagnostic Challenges. Archives of Plastic Surgery, 2015, 42, 261-263.	0.9	14
49	Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas.. Journal of Clinical Oncology, 2015, 33, e20042-e20042.	1.6	0
50	Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival.. Journal of Clinical Oncology, 2015, 33, 9070-9070.	1.6	0
51	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. Journal of Translational Medicine, 2014, 12, 342.	4.4	24
52	Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial. Breast Cancer Research, 2014, 16, 463.	5.0	17
53	Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?. Human Pathology, 2014, 45, 1656-1663.	2.0	12
54	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, 9086-9086.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma.. Journal of Clinical Oncology, 2014, 32, 9072-9072.	1.6	0
56	Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.. Journal of Clinical Oncology, 2014, 32, 3030-3030.	1.6	0
57	Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).. Journal of Clinical Oncology, 2013, 31, 60-60.	1.6	1
58	Impact of age on treatment of primary melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9054-9054.	1.6	0
59	Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).. Journal of Clinical Oncology, 2013, 31, 11106-11106.	1.6	0
60	Analysis of plasma-based <i>BRAF</i> and <i>NRAS</i> mutation detection in patients with stage III and IV melanoma.. Journal of Clinical Oncology, 2013, 31, 9023-9023.	1.6	0
61	Targeting BET proteins in melanoma: A novel treatment approach.. Journal of Clinical Oncology, 2013, 31, 9091-9091.	1.6	1
62	Histology-Specific MicroRNA Alterations in Melanoma. Journal of Investigative Dermatology, 2012, 132, 1860-1868.	0.7	46
63	Intra- and Inter-Tumor Heterogeneity of BRAFV600E Mutations in Primary and Metastatic Melanoma. PLoS ONE, 2012, 7, e29336.	2.5	250
64	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology, 2012, 30, 2589-2589.	1.6	3
65	Early alterations of microRNA expression to predict and modulate melanoma metastasis.. Journal of Clinical Oncology, 2012, 30, 8550-8550.	1.6	0
66	Prognostic value of mitosis-specific antibodies and computer image analysis in calculating mitotic rate in melanoma.. Journal of Clinical Oncology, 2012, 30, e19003-e19003.	1.6	0
67	TILs in metastatic melanoma tumors: A biomarker for immunotherapy?. Journal of Clinical Oncology, 2012, 30, 8589-8589.	1.6	0
68	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American Journal of Translational Research (discontinued), 2009, 1, 35-43.	0.0	33
69	Atypia on breast core needle biopsies: reproducibility and significance. Annals of Clinical and Laboratory Science, 2009, 39, 270-6.	0.2	27